<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940110-0-00035</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=85 g=1 f=1 --> List of Subjects  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 42 CFR Part 405  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Administrative practice and procedure, Health facilities,  <!-- PJG 0012 frnewline --> Health professions, Kidney disease, Laboratories, Medicare,  <!-- PJG 0012 frnewline --> Reporting and recordkeeping requirements, Rural areas, X-rays.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 42 CFR Part 410  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Health facilities, Health professions, Kidney diseases,  <!-- PJG 0012 frnewline --> Laboratories, Medicare, Rural areas, X-rays.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 42 CFR Part 413  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Health facilities, Kidney diseases, Medicare, Puerto Rico,  <!-- PJG 0012 frnewline --> Reporting and recordkeeping requirements.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 42 CFR Part 414  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> End-stage renal (ESRD), Health professions, Laboratories,  <!-- PJG 0012 frnewline --> Medicare.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=76 g=1 f=1 --> 42 CFR CHAPTER IV HEALTH CARE FINANCING ADMINISTRATION,  <!-- PJG 0012 frnewline --> DEPARTMENT OF HEALTH AND HUMAN SERVICES  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The interim rule with comment period that was published  <!-- PJG 0012 frnewline --> on September 4, 1991, at 56 FR 43706, to amend Parts 405,  <!-- PJG 0012 frnewline --> 410, 413, and 414 of this chapter is adopted as final with  <!-- PJG 0012 frnewline --> the changes set forth below.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=56 g=1 f=1 --> PART 405_FEDERAL HEALTH INSURANCE FOR THE AGED AND  <!-- PJG 0012 frnewline --> DISABLED  <!-- PJG 0012 frnewline --> Subpart U_Conditions for Coverage of Suppliers of End-Stage Renal Disease (ESRD) Services  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for subpart U continues to  <!-- PJG 0012 frnewline --> read as follows:  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority: <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Secs. 1102, 1861, 1862(a), 1871, 1874, and  <!-- PJG 0012 frnewline --> 1881 of the Social Security Act (42 U.S.C. 1302, 1395x,  <!-- PJG 0012 frnewline --> 1395y(a), 1395hh, 1395kk, and 1395rr), unless otherwise  <!-- PJG 0012 frnewline --> noted. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 405.2137 is amended to revise paragraph  <!-- PJG 0012 frnewline --> (b)(7), to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;405.2137  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Condition: Patient long-term program and  <!-- PJG 0012 frnewline --> patient care plan.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standard: Patient care plan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . * * *  <!-- PJG 0012 frnewline --> (7) For a home dialysis patient who uses EPO in the  <!-- PJG 0012 frnewline --> home, the plan must provide for monitoring home use of EPO  <!-- PJG 0012 frnewline --> that includes the following:  <!-- PJG 0012 frnewline --> (i) Review of diet and fluid intake for indiscretions  <!-- PJG 0012 frnewline --> as indicated by hyperkalemia and elevated blood pressure  <!-- PJG 0012 frnewline --> secondary to volume overload.  <!-- PJG 0012 frnewline --> (ii) Review of medications to ensure adequate provision  <!-- PJG 0012 frnewline --> of supplemental iron.  <!-- PJG 0012 frnewline --> (iii) Ongoing evaluations of hematocrit and iron  <!-- PJG 0012 frnewline --> stores.  <!-- PJG 0012 frnewline --> (iv) A reevaluation of the dialysis prescription taking  <!-- PJG 0012 frnewline --> into account the patient's increased appetite and red blood  <!-- PJG 0012 frnewline --> cell volume.  <!-- PJG 0012 frnewline --> (v) A method for physician followup on blood tests and  <!-- PJG 0012 frnewline --> a mechanism (such as a patient log) for keeping the  <!-- PJG 0012 frnewline --> physician informed of the results.  <!-- PJG 0012 frnewline --> (vi) Training of the patient to identify the signs and  <!-- PJG 0012 frnewline --> symptoms of hypotension and hypertension.  <!-- PJG 0012 frnewline --> (vii) The decrease or discontinuance of EPO if  <!-- PJG 0012 frnewline --> hypertension is uncontrollable.  <!-- PJG 0012 frnewline --> 3. Section 405.2163 is amended to revise paragraph (g)  <!-- PJG 0012 frnewline --> and add a new paragraph (h), to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;405.2163  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Condition: Minimal service requirements for a  <!-- PJG 0012 frnewline --> renal dialysis facility or renal dialysis center.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (g)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Use of EPO at home: Patient selection.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The  <!-- PJG 0012 frnewline --> dialysis facility, or the physician responsible for all  <!-- PJG 0012 frnewline --> dialysis-related services furnished to the patient, must  <!-- PJG 0012 frnewline --> make a comprehensive assessment that includes the following:  <!-- PJG 0012 frnewline --> (1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pre-selection monitoring.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The patient's hematocrit  <!-- PJG 0012 frnewline --> (or hemoglobin), serum iron, transferrin saturation, serum  <!-- PJG 0012 frnewline --> ferritin, and blood pressure must be measured.  <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Conditions the patient must meet.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The assessment must  <!-- PJG 0012 frnewline --> find that the patient meets the following conditions:  <!-- PJG 0012 frnewline --> (i) Is a home dialysis patient.  <!-- PJG 0012 frnewline --> (ii) Has a hematocrit (or comparable hemoglobin level)  <!-- PJG 0012 frnewline --> that is as follows:  <!-- PJG 0012 frnewline --> (A) For a patient who is initiating EPO treatment, no  <!-- PJG 0012 frnewline --> higher than 30 percent unless there is medical documentation  <!-- PJG 0012 frnewline --> showing the need for EPO despite a hematocrit (or comparable  <!-- PJG 0012 frnewline --> hemoglobin level) higher than 30 percent. (Patients with  <!-- PJG 0012 frnewline --> severe angina, severe pulmonary distress, or severe  <!-- PJG 0012 frnewline --> hypertension may require EPO to prevent adverse symptoms  <!-- PJG 0012 frnewline --> even if they have higher hematocrit or hemoglobin levels.)  <!-- PJG 0012 frnewline --> (B) For a patient who has been receiving EPO from the  <!-- PJG 0012 frnewline --> facility or the physician, between 30 and 33 percent.  <!-- PJG 0012 frnewline --> (iii) Is under the care of_ <!-- PJG 0012 frnewline --> (A) A physician who is responsible for all dialysis-related services and who prescribes the EPO and follows the  <!-- PJG 0012 frnewline --> drug labeling instructions when monitoring the EPO home  <!-- PJG 0012 frnewline --> therapy; and  <!-- PJG 0012 frnewline --> (B) A renal dialysis facility that establishes the plan  <!-- PJG 0012 frnewline --> of care and monitors the progress of the home EPO therapy.  <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Conditions the patient or the patient's caregiver  <!-- PJG 0012 frnewline --> must meet.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The assessment must find that the patient or a  <!-- PJG 0012 frnewline --> caregiver who assists the patient in performing self-dialysis meets the following conditions:  <!-- PJG 0012 frnewline --> (i) Is trained by the facility to inject EPO and is  <!-- PJG 0012 frnewline --> capable of carrying out the procedure.  <!-- PJG 0012 frnewline --> (ii) Is capable of reading and understanding the drug  <!-- PJG 0012 frnewline --> labeling.  <!-- PJG 0012 frnewline --> (iii) Is trained in, and capable of observing, aseptic  <!-- PJG 0012 frnewline --> techniques.  <!-- PJG 0012 frnewline --> (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Care and storage of drug.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The assessment must  <!-- PJG 0012 frnewline --> find that EPO can be stored in the patient's residence under  <!-- PJG 0012 frnewline --> refrigeration and that the patient is aware of the potential  <!-- PJG 0012 frnewline --> hazard of a child's having access to the drug and syringes.  <!-- PJG 0012 frnewline --> (h)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Use of EPO at home: Responsibilities of the  <!-- PJG 0012 frnewline --> physician or the dialysis facility.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The patient's physician  <!-- PJG 0012 frnewline --> or dialysis facility must_ <!-- PJG 0012 frnewline --> (1) Develop a protocol that follows the drug label  <!-- PJG 0012 frnewline --> instructions;  <!-- PJG 0012 frnewline --> (2) Make the protocol available to the patient to  <!-- PJG 0012 frnewline --> ensure safe and effective home use of EPO; and  <!-- PJG 0012 frnewline --> (3) Through the amounts prescribed, ensure that the  <!-- PJG 0012 frnewline --> drug ``on hand'' at any time does not exceed a 2-month supply.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            